(GRDN) Guardian Pharmacy Services - Overview

Sector: HealthcareIndustry: Medical Care Facilities | Exchange NYSE (USA) | Currency USD | Market Cap: 2.198m | Total Return 75.2% in 12m

Stock Pharmacy Services, Technology, Data Analytics, Drug Management
Total Rating 75
Risk 88
Buy Signal 0.67
Medical Care Facilities -7.5
Drug Retail +20.8
Market Cap: 2,198m
Avg Trading Vol: 16.4M USD
ATR: 4.94%
Peers RS (IBD): 91.9
Risk 5d forecast
Volatility61.5%
Rel. Tail Risk-4.37%
Reward TTM
Sharpe Ratio1.49
Alpha66.82
Character TTM
Beta0.636
Beta Downside0.578
Drawdowns 3y
Max DD27.21%
CAGR/Max DD2.80
EPS (Earnings per Share) EPS (Earnings per Share) of GRDN over the last years for every Quarter: "2021-03": null, "2021-09": null, "2021-12": null, "2022-03": null, "2022-06": null, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": null, "2024-06": 0.245, "2024-09": -2, "2024-12": 0.2381, "2025-03": 0.19, "2025-06": 0.23, "2025-09": 0.25, "2025-12": 0.37, "2026-03": 0,
EPS CAGR: -6.32%
EPS Trend: 36.3%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of GRDN over the last years for every Quarter: 2021-03: 181.311, 2021-09: 203.589, 2021-12: 209.886, 2022-03: 211.049, 2022-06: 224.078, 2022-09: 236.891, 2022-12: 236.891, 2023-03: 248.946, 2023-06: 253.439, 2023-09: 262.741, 2023-12: 281.067, 2024-03: 275.41, 2024-06: 300.037, 2024-09: 314.393, 2024-12: 338.569, 2025-03: 329.308, 2025-06: 344.334, 2025-09: 377.427, 2025-12: 397.616, 2026-03: null,
Rev. CAGR: 18.40%
Rev. Trend: 99.2%
Qual. Beats: 0
Description: GRDN Guardian Pharmacy Services March 05, 2026

Guardian Pharmacy Services, Inc. (GRDN) is a pharmacy service company. It provides technology-enabled services to long-term care facilities (LTCFs) in the United States. This sector is characterized by specialized medication management needs for vulnerable populations.

The company focuses on lower acuity LTCFs, including assisted living, behavioral health, and group homes. Its business model involves individualized clinical support, drug dispensing, and administration. This niche market requires tailored solutions beyond traditional retail pharmacy.

GRDN offers proprietary technology solutions. Guardian Compass provides operational dashboards for its pharmacies. GuardianShield Programs support LTCFs. The Order Entry QA Analyzer uses real-time rules to detect prescription errors. The Medication Spend Analyzer details drug costs for LTCFs. Further research on ValueRay can provide deeper insights into GRDNs competitive landscape and financial performance.

Founded in 2003, Guardian Pharmacy Services, Inc. is headquartered in Atlanta, Georgia.

Headlines to Watch Out For
  • LTCF resident growth directly impacts pharmacy service demand
  • Technology-enabled services drive operational efficiency and client retention
  • Regulatory changes in long-term care sector pose compliance risks
  • Healthcare staffing shortages increase demand for outsourced pharmacy solutions
Piotroski VR‑10 (Strict, 0-10) 6.5
Net Income: 49.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA 6.59 > 1.0
NWC/Revenue: 4.21% < 20% (prev 0.64%; Δ 3.57% < -1%)
CFO/TA 0.24 > 3% & CFO 100.3m > Net Income 49.2m
Net Debt (-20.9m) to EBITDA (102.7m): -0.20 < 3
Current Ratio: 1.38 > 1.5 & < 3
Outstanding Shares: last quarter (63.6m) vs 12m ago 4.05% < -2%
Gross Margin: 19.47% > 18% (prev 0.20%; Δ 1.93k% > 0.5%)
Asset Turnover: 395.0% > 50% (prev 382.9%; Δ 12.11% > 0%)
Interest Coverage Ratio: 119.4 > 6 (EBITDA TTM 102.7m / Interest Expense TTM 665k)
Altman Z'' 3.31
A: 0.15 (Total Current Assets 221.6m - Total Current Liabilities 160.7m) / Total Assets 412.7m
B: 0.16 (Retained Earnings 66.3m / Total Assets 412.7m)
C: 0.22 (EBIT TTM 79.4m / Avg Total Assets 366.7m)
D: 0.34 (Book Value of Equity 66.4m / Total Liabilities 194.7m)
Altman-Z'' Score: 3.31 = A
Beneish M -3.17
DSRI: 0.89 (Receivables 101.6m/97.2m, Revenue 1.45b/1.23b)
GMI: 1.02 (GM 19.47% / 19.89%)
AQI: 0.87 (AQ_t 0.24 / AQ_t-1 0.28)
SGI: 1.18 (Revenue 1.45b / 1.23b)
TATA: -0.12 (NI 49.2m - CFO 100.3m) / TA 412.7m)
Beneish M-Score: -3.17 (Cap -4..+1) = AA
What is the price of GRDN shares? As of March 31, 2026, the stock is trading at USD 37.25 with a total of 747,898 shares traded.
Over the past week, the price has changed by -0.03%, over one month by +11.16%, over three months by +23.10% and over the past year by +75.21%.
Is GRDN a buy, sell or hold? Guardian Pharmacy Services has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy GRDN.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the GRDN price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 38.5 3.4%
Analysts Target Price 38.5 3.4%
GRDN Fundamental Data Overview March 30, 2026
P/E Trailing = 43.7949
P/E Forward = 29.1545
P/S = 1.5172
P/B = 10.9618
Revenue TTM = 1.45b USD
EBIT TTM = 79.4m USD
EBITDA TTM = 102.7m USD
Long Term Debt = 37.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 44.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -20.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.18b USD (2.20b + Debt 44.7m - CCE 65.6m)
Interest Coverage Ratio = 119.4 (Ebit TTM 79.4m / Interest Expense TTM 665k)
EV/FCF = 26.97x (Enterprise Value 2.18b / FCF TTM 80.7m)
FCF Yield = 3.71% (FCF TTM 80.7m / Enterprise Value 2.18b)
FCF Margin = 5.57% (FCF TTM 80.7m / Revenue TTM 1.45b)
Net Margin = 3.40% (Net Income TTM 49.2m / Revenue TTM 1.45b)
Gross Margin = 19.47% ((Revenue TTM 1.45b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 18.82% (prev 19.80%)
Tobins Q-Ratio = 5.28 (Enterprise Value 2.18b / Total Assets 412.7m)
Interest Expense / Debt = 0.36% (Interest Expense 163k / Debt 44.7m)
Taxrate = 31.62% (9.83m / 31.1m)
NOPAT = 54.3m (EBIT 79.4m * (1 - 31.62%))
Current Ratio = 1.38 (Total Current Assets 221.6m / Total Current Liabilities 160.7m)
Debt / Equity = 0.22 (Debt 44.7m / totalStockholderEquity, last quarter 205.8m)
Debt / EBITDA = -0.20 (Net Debt -20.9m / EBITDA 102.7m)
Debt / FCF = -0.26 (Net Debt -20.9m / FCF TTM 80.7m)
Total Stockholder Equity = 178.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.42% (Net Income 49.2m / Total Assets 412.7m)
RoE = 27.53% (Net Income TTM 49.2m / Total Stockholder Equity 178.8m)
RoCE = 36.78% (EBIT 79.4m / Capital Employed (Equity 178.8m + L.T.Debt 37.1m))
RoIC = 30.38% (NOPAT 54.3m / Invested Capital 178.8m)
WACC = 8.06% (E(2.20b)/V(2.24b) * Re(8.22%) + D(44.7m)/V(2.24b) * Rd(0.36%) * (1-Tc(0.32)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.25%
[DCF] Terminal Value 81.06% ; FCFF base≈65.1m ; Y1≈78.3m ; Y5≈126.3m
[DCF] Fair Price = 58.30 (EV 2.15b - Net Debt -20.9m = Equity 2.17b / Shares 37.3m; r=8.06% [WACC]; 5y FCF grow 21.77% → 3.0% )
EPS Correlation: 36.29 | EPS CAGR: -6.32% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.16 | Revenue CAGR: 18.40% | SUE: N/A | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.27 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=1.24 | Chg7d=+0.110 | Chg30d=+0.110 | Revisions Net=+4 | Growth EPS=+15.4% | Growth Revenue=-2.4%
EPS next Year (2027-12-31): EPS=1.36 | Chg7d=+0.095 | Chg30d=+0.095 | Revisions Net=+4 | Growth EPS=+9.9% | Growth Revenue=+7.9%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.9% (Discount Rate 8.2% - Earnings Yield 2.3%)
[Growth] Growth Spread = -6.7% (Analyst -0.7% - Implied 5.9%)
Additional Sources for GRDN Stock Fund Manager Positions: Dataroma · Stockcircle